年次学会

第4回OOTR年次学会

新たながん治療戦略の創造を目指して
- 基礎から臨床へ -

開催日時 平成19年11月9日(金) - 10日(土)
開催場所 国立京都国際会館イベントホール
プログラム ( プログラムのダウンロードはこちら )
スピーカー
学会レポート
学会写真

プログラム ( プログラムのダウンロードはこちら )

11月9日

Time Title Topic Theme Speakers
8:55 Opening Remarks
9:00 Symposium-1 Angiogenesis, Lymphangiogenesis and Their Inhibitions Interplay Between Tumor-derived Angiogenic Factors Cao YH
Novel Function of Int6/HIF2α Pathway in Neovasculization and Tumorigenesis Shibasaki F
Arf6 Constitutes a Central Pathway Involved in Breast Cancer Cell Invasion and Metastasis Sabe H
Antiangiogenic Therapy of Locally Advanced Rectal Cancer Gasparini G
Break
11:20 Plenary Lecture-1 Cancer Prevention Frontier
Lunch Preparation
12:10 Luncheon Seminar Molecular Mechanism of Anti-Cancer Therapies Molecular Mechanism of Anti-Cancer Therapies Saya H
Break
13:10 Symposium-2 Growth Factor and Growth Factor Receptors Targeting Growth Factor Signaling for Therapeutic Benefits in Cancer Cells Kumar R
EGFR and HER2: Ample Opportunities for Next-Generation Cancer Therapeutics Yarden Y
Signaling Proteome of Breast Cancer by High Accuracy-Mass Spectrometry Ishihama Y
Quantitative HER2 Expression and Clinical Outcomes in Patients with Trastuzumab-Treated Metastatic Breast Cancer Bates M
Break
15:50 Keynote Lecture-1 Application of Cell Cycle Profiling to Prediction of Recurrence and Response to Chemotherapy in Human Breast Cancers Application of Cell Cycle Profiling to Prediction of Recurrence and Response to Chemotherapy in Human Breast Cancers Noguchi S
16:30 Keynote Lecture-2 Cancer Therapy in The Adjuvant Setting: Issues and Perspectives Cancer Therapy in The Adjuvant Setting: Issues and Perspectives Gluck S
17:10 Session-1 Pharmacoeconomics of Target Therapy The Cost-Effectiveness of Monoclonal Antibodies in the Treatment of Breast and Colorectal Cancer Norum J
Economic Evaluations at Gene Diagnostic Technologies and Prospect at Those Impact on Health Financing Kondo M
Break
18:45 Music Concert Horn Trio(Horn, Piano, Violin) : World's leading Hornist, Nobuyuki Mizuno, will play Mozart , etc.
19:30 Gala Dinner

11月10日

Time Title Topic Theme Speakers
9:00 Symposium-3 Steroid Hormones and Their Manipulation Upfront Hormonal Therapy and the Future Perspectives Lonning P
Development of Intracrinology and its Manipulation Sasano H
10:10 Plenary Lecture-2 Induction of Pluripotency by Defined Factors Induction of Pluripotency by Defined Factors Yamanaka S
Break
11:10 OOTR Special Lecture Ubiquitin-mediated Intracellular Protein Degradation: From Basic Mechanisms thru Human Diseases and onto Drug Targeting
Lunch
12:40 Poster Discussion
13:20 Session-2 New Therapeutic Approaches Anticancer activity and molecular target of an NF-κB inhibitor, DHMEQ Umezawa K
Non-Fucosylated Antibodies as Next-Generation Therapeutic Antibodies: Mechanism of Enhanced Adcc of Non-Fucosylated Antibodies in Human Blood Shitara K
14:10 Plenary Lecture-3 Metoronomic Chemotherapy with a Targeted Antiangiogenic Drug for Treatment of Advanced Metastatic Disease Metoronomic Chemotherapy with a Targeted Antiangiogenic Drug for Treatment of Advanced Metastatic Disease Kerbel R
Break
15:00 Keynote-Address
15:15 Panel Discussion
  Award Presentation
17:00 Closing Remarks

スピーカー

OOTR Special Lecture
by Proferssor Aaron Ciechanover

Nobel Prize Laureate in Chemistry 2004

He discovered Ubiquitin-mediated Intracellular Protein Degradation.

Nadir Arber,

Tel Aviv University
Israel

Michael Bates,

Monogram Biosciences Inc.
USA

Yihai Cao,

Karolinska Institute
Sweden

Louis W.C. Chow,

UNIMED Medical Institute / Hong Kong University
Hong Kong, SAR

Aaron Ciechanover

Technion-Israel Institute of Technology
Israel

Giampietro Gasparini,

University of Rome
Italy

Stefan Gluck,

University of Miami
USA

Yasushi Ishihama,

Keio University
Japan

Robert S. Kerbel,

Sunnybrook Health Sciences Centre
Canada

Masahide Kondo,

Tsukuba University
Japan

Rakesh Kumar,

M. D. Anderson Cancer Center
USA

Per Lonning,

University of Bergen
Norway

Shinzaburo Noguchi,

Osaka University
Japan

Jan Norum,

University Hospital of North Norway
Norway

Hisataka Sabe,

Osaka Bio Science Institute
Japan

Hironobu Sasano,

Tohoku University
Japan

Hideyuki Saya,

Keio University
Japan

Futoshi Shibasaki,

Tokyo Metropolitan Institute of Medical Science
Japan

Kenya Shitara,

Kyowa Hakko Kogyo Co.
Japan

Masakazu Toi,

Kyoto University
Japan

Kazuo Umezawa,

Keio University
Japan

Shinya Yamanaka,

Kyoto University
Japan

Yosef Yarden,

Weizmann Institute
Israel

(アルファベット順)

学会レポート

9 November, 2007

Symposium-1

Dr. Cao addressed the cross-talk between vascular endothelial growth factor receptor (VEGFR)-axis and platelet-derived growth factor receptor (PDGFR) in the endothelium. He also indicated the significance of lymphangiogenesis in tumor biology. Several possible therapeutic strategies were introduced based upon these results.

Dr. Shibasaki demonstrated that the stabilization control of hypoxia-inducible factor (HIF) 2α through the tumor suppressor Int6/eIF3e is the master switch in the formation of normal neovessels. He suggested that siRNA-Int6, which could down-regulate Int6/eIF3e expression, may be useful for clinical therapy.

Dr. Gasparini introduced the phase II study of locally advanced rectal cancer. In this study, the addition of Bevacizumab, a recombinant humanized antibody against VEGF, to Capecitabine and radiotherapy was feasible and well tolerated.

Plenary Lecture-1

Dr. Arber presented several newly developed methods of screening for colorectal cancer. He also summarized some chemoprevention studies, Adenoma Prevention with Celecoxib (APC) study, Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) study, and Adenomatous Polyp Prevention on Vioxx (APPROVe) study.

Luncheon Seminar

Dr. Saya proposed the new resistance mechanisms against chemotherapeutic agents, such as paclitaxel. He presented that dysfunction of mitotic checkpoint, treatment with anti-oxidants, and p38 inhibitor may confer resistance to the agents.

Symposium-2

Dr. Kumar said about targeting growth factor signaling for therapeutic benefits in cancer cells. This presentation was interested that the pathogenesis of epithelial cancer is influenced by the signaling cascades downstream of the human epidermal growth factor receptor family of receptor tyrosine kinase and by the HER ligands.

Dr. Ishihama said about signaling proteome of breast cancer by high-accuracy mass spectrometry. This presentation was interested in the influence of estradiol treatment on the time-resolved phosphorylation of proteins belonging to EGFR signaling pathway.

Dr. Bates said about quantitative HER2 expression and clinical outcomes in patients with trastuzumab-treated metastatic breast cancer. This presentation was interested that their data confirm prior observations of a continuum of trastuzumab responsiveness related to quantitative amount of HER2 expression or homodimers as measured by VeraTag.

Keynote Lecture-2

Dr. Gluck said about neoadjuvant therapy in breast cancer. This presentation was interested in showing recently study about neoadjuvant therapy and new combination therapy.

Session-1

Dr. Norum talked about the cost-effectiveness of trastuzumab in adjuvant breast cancer therapy in Norway. In metastatic setting, the figure is around frequently employed cut-off levels. In metastatic colorectal cancer there are no solid data on cetuximab or bevacizumab indication the cost per life year gained being less than accepted limits.

Dr. Kondo presented economic evaluations of a recently developed gene diagnostic technology, 21-gene signature of breast cancer, and its impact on health financing.

10 November, 2007

Symposium-3

Dr. Lonning addressed several important questions concerning hormonal therapy, current trials for premenopausals using combined treatment with an LH-RH analogue and an aromatase inhibitor, optimal use of aromatase inhibitor for postmenopausals, and optimal duration of therapy.

Dr. Sasano focused on the importance of the development of new modes of endocrine therapy based on “intracrine” concepts. Not only aromatase inhibitors, but also other enzymes such as 17β-hydroxysteroid dehydrogenase (17β-HSD) isozymes, estrogen sulfatase (STS), and estrogen sulfotransferase, play pivotal roles in endocrine therapy of postmenopausal breast cancer patients.

Session-2

Dr. Umezawa presented anticancer activity and molecular target of a NK-κB inhibitor, dehydroxymethyleproxyquinomicin (DHMEQ). He also mentioned resistomycin and 9-methylstreptimidone as new NF-κB inhibitors.

Plenary Lectur-3

Dr. Kerbel presented metronomic chemotherapy combined with an antiangiogenic drug, such as bevacizumab, moved into phase Ⅱ clinical trial. He also showed that combination chemotherapy using cyclophosphamide and UFT might be particularly promising for metronomic chemotherapy in these indications.

学会写真

会場外観
会場外観
案内表示
案内表示
ポスターディスカッション風景
ポスター
ディスカッション風景
パネルディスカッション
パネルディスカッション

ootr.org